Anthony Propst MD

Anthony Propst, MD – Austin and Round Rock Fertility Specialist

Anthony M. Propst, MD Round Rock Fertility SpecialistAnthony “Tony” Propst is a Reproductive Endocrinology and Infertility Specialist at Texas Fertility Center in Austin and Round Rock, Texas.He joined TFC in 2013 after retiring from the United States Air Force at the rank of Colonel after 21 years of service.

Originally from Morganton, North Carolina, Dr. Propst received a U.S. Congressional appointment to the United States Air Force Academy and attended medical school at the University of North Carolina School of Medicine. Dr. Propst completed his internship and residency at David Grant USAF Medical Center, Travis AFB, California, and fellowship training in Reproductive Endocrinology at Brigham and Women’s Hospital – Harvard Medical School.


Anthony Propst, MD, Board Certified Fertility Specialist

During his Air Force career, Dr Propst was Chief of Reproductive Endocrinology at Wilford Hall USAF Medical Center, San Antonio, Texas and Keesler USAF Medical Center, Biloxi, Mississippi. He is a former Chief Consultant to the USAF Surgeon General for Obstetrics and Gynecology. In his last assignment, he was an Associate Professor of Ob/Gyn and Associate Fellowship Director of the NIH-Uniformed Services University Fellowship in Reproductive Endocrinology in Bethesda, Maryland.

Dr. Propst is board-certified in both Obstetrics and Gynecology, and Reproductive Endocrinology and Infertility. He is a member of the American Society of Reproductive Medicine, Society for Reproductive Endocrinology and Infertility, and the American College of Obstetricians and Gynecologists. He is a member of the Practice Committee of the Society of Assisted Reproduction. He has authored 23 original research articles and multiple invited reviews and book chapters.

Click Here for Dr. Propst’s CV

Anthony M. Propst, MD Fertility Videos

Fertility Medications for Ovarian Stimulation Fertility Robotic Surgery at Our Austin Fertility Center  Egg Freezing Options

Dr. Propst’s Fertility Research

2015 Devine K, Mumford SL, Wu M, DeCherney AH, Hill MJ, Propst A. Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. Fertil Steril.2015;104:612-19.
2015 Devine K, Mumford SL, Goldman KN, Hodes-Wertz B, Druckenmiller S, Propst AM, Noyes N. Baby budgeting: oocyte cryopreservation in women delaying reproduction can reduce cost per live birth. Fertil Steril. 2015;103:1446-53.
2015 Connell MT, Szatkowski JM, Terry N, DeCherney AH, Propst AM, Hill MJ. Timing luteal support in assisted reproductive technology: a systematic review. Fertil Steril. 2015;103:939-946.
2015 Whitehurst SV, Lockrow EG, Lendvay TS, Propst AM, Dunlow SG, Rosemeyer CJ, Gobern JM, White LW, Skinner A, Buller JL. Comparison of two simulation systems to support robotic-assisted surgical training: a pilot study (Swine model). J Minim Invasive Gynecol. 2015;22:483-8.
2014 Levy G, Hill M, Beall S, Pilgrim JD, Payson M, Propst A. Falling estradiol levels on day after human chorionic gonadotropin administration in assisted reproductive technology cycles are not predictive of decreasing oocyte maturity or pregnancy rates. J Reprod Med. 2014;59:255-9.
2013 Hill MJ, Whitcomb BW, Lewis TD, Wu M, Terry N, DeCherney AH, Levens ED, Propst AM. Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis. Fertil Steril 2013;100:1373-80.
2012 Royster GD, Retzloff MG, Robinson RD, King JA, Propst AM. Effect of length of controlled ovarian hyperstimulation using a gonadotropin-releasing hormone antagonist on in vitro fertilization pregnancy rates. J Reprod Med. 2012;57(9-10):415-20.
2012 Wu M, Henne M, Propst A. Tax Credits, insurance, and in vitro fertilization in the military. Military Medicine 2012;177(6):745-7.
2011 Propst AM, Hill MJ, Bates GW, Palumbo M, Van Horne AK, Retzloff MG. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril 2011;96(4):898-904.
2011 Fausett MB, Propst AM, Van Doren K, Clark BT. How To Develop An Effective Obstetric Checklist. Am J Obstet Gynecol, 2011;205(3):165-70.
2009 Fritz MA, Ory SJ, Barnhart KT, Catherino WH, Cedars MI, Collins J, Goldberg JM, Gracia C, Licht M, Liu JH, Racowsky C, Schering-Plough, Schattman G, Schering-Plough,Thomas MA, Rebar RW, La Barbera AR, Schattman G, Schering-Plough, Battaglia D, Propst A, Reed M, Sakkas D, Sharara F, Schering-Plough, Vernon M, Widra E. Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology. Guidelines on number of embryos transferred. Fertil Steril 2009;92(5):1518-9.
2009 Beesley R, Robinson R, Propst A, Arthur N, Retzloff M. Impact of day 3 or day 5 embryo transfer on pregnancy rates and multiple gestations. Fertil Steril 2009;91(5):1717-20.

For More TFC Fertility Research